Literature DB >> 9108071

Genotypes at the GluR6 kainate receptor locus are associated with variation in the age of onset of Huntington disease.

D C Rubinsztein1, J Leggo, M Chiano, A Dodge, G Norbury, E Rosser, D Craufurd.   

Abstract

Huntington disease (HD) is associated with abnormal expansions of a CAG repeat close to the 5' end of the IT15 gene. We have assembled a set of 293 HD subjects whose ages of onset were known and sized their HD CAG repeats. These repeats accounted for 69% of the variance of age of onset when we used the most parsimonious model, which relates the logarithm of age of onset to a function of CAG repeat number. Since other familial factors have been proposed to influence the age of onset of HD, we have examined a number of candidate loci. The CAG repeat number on normal chromosomes, the delta2642 polymorphism in the HD gene, and apolipoprotein E genotypes did not affect the age of onset of HD. Although mitochondrial energy production defects in HD have led to suggestions that variants in the mitochondrial genome may be associated with clinical variability in HD, this suggestion was not supported by our preliminary experiments that examined the DdeI mitochondrial restriction fragment length polymorphism at position 10,394. Excitotoxicity has been a favored mechanism to explain the cell death in HD, particularly since intrastriatal injection of excitatory amino acids in animals creates HD-like pathology. Accordingly, we investigated the GluR6 kainate receptor. Of the variance in the age of onset of HD that was not accounted for by the CAG repeats, 13% could be attributed to GluR6 genotype variation. These data implicate GluR6-mediated excitotoxicity in the pathogenesis of HD and highlight the potential importance of this process in other polyglutamine repeat expansion diseases.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9108071      PMCID: PMC20534          DOI: 10.1073/pnas.94.8.3872

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  24 in total

1.  Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.

Authors:  J E Hixson; D T Vernier
Journal:  J Lipid Res       Date:  1990-03       Impact factor: 5.922

2.  Apolipoprotein E type epsilon 4 allele frequency is increased in patients with schizophrenia.

Authors:  C R Harrington; M Roth; J H Xuereb; P J McKenna; C M Wischik
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

3.  Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy.

Authors:  B G Jenkins; W J Koroshetz; M F Beal; B R Rosen
Journal:  Neurology       Date:  1993-12       Impact factor: 9.910

4.  Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients.

Authors:  J M Shoffner; M D Brown; A Torroni; M T Lott; M F Cabell; S S Mirra; M F Beal; C C Yang; M Gearing; R Salvo
Journal:  Genomics       Date:  1993-07       Impact factor: 5.736

5.  The relationship between trinucleotide (CAG) repeat length and clinical features of Huntington's disease.

Authors:  S E Andrew; Y P Goldberg; B Kremer; H Telenius; J Theilmann; S Adam; E Starr; F Squitieri; B Lin; M A Kalchman
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

6.  Relationship between trinucleotide repeat expansion and phenotypic variation in Huntington's disease.

Authors:  R G Snell; J C MacMillan; J P Cheadle; I Fenton; L P Lazarou; P Davies; M E MacDonald; J F Gusella; P S Harper; D J Shaw
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

7.  Trinucleotide repeat length instability and age of onset in Huntington's disease.

Authors:  M Duyao; C Ambrose; R Myers; A Novelletto; F Persichetti; M Frontali; S Folstein; C Ross; M Franz; M Abbott
Journal:  Nat Genet       Date:  1993-08       Impact factor: 38.330

8.  The normal Huntington disease (HD) allele, or a closely linked gene, influences age at onset of HD.

Authors:  L A Farrer; L A Cupples; P Wiater; P M Conneally; J F Gusella; R H Myers
Journal:  Am J Hum Genet       Date:  1993-07       Impact factor: 11.025

9.  Apolipoprotein E4 and Alzheimer's disease pathology in Lewy body disease and in other beta-amyloid-forming diseases.

Authors:  S M Pickering-Brown; D M Mann; J P Bourke; D A Roberts; D Balderson; A Burns; J Byrne; F Owen
Journal:  Lancet       Date:  1994-05-07       Impact factor: 79.321

10.  Molecular analysis of late onset Huntington's disease.

Authors:  B Kremer; F Squitieri; H Telenius; S E Andrew; J Theilmann; N Spence; Y P Goldberg; M R Hayden
Journal:  J Med Genet       Date:  1993-12       Impact factor: 6.318

View more
  61 in total

1.  Subcellular and subsynaptic localization of presynaptic and postsynaptic kainate receptor subunits in the monkey striatum.

Authors:  J Z Kieval; G W Hubert; A Charara; J F Paré; Y Smith
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

2.  Glutamine/proline-rich PQE-1 proteins protect Caenorhabditis elegans neurons from huntingtin polyglutamine neurotoxicity.

Authors:  Peter W Faber; Cindy Voisine; Daphne C King; Emily A Bates; Anne C Hart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-12-16       Impact factor: 11.205

Review 3.  Huntington's disease: a decade beyond gene discovery.

Authors:  Penelope Hogarth
Journal:  Curr Neurol Neurosci Rep       Date:  2003-07       Impact factor: 5.081

4.  TAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.

Authors:  Ji-Hyun Lee; Jong-Min Lee; Eliana Marisa Ramos; Tammy Gillis; Jayalakshmi S Mysore; Shotaro Kishikawa; Tiffany Hadzi; Audrey E Hendricks; Michael R Hayden; Patrick J Morrison; Martha Nance; Christopher A Ross; Russell L Margolis; Ferdinando Squitieri; Cinzia Gellera; Estrella Gomez-Tortosa; Carmen Ayuso; Oksana Suchowersky; Ronald J Trent; Elizabeth McCusker; Andrea Novelletto; Marina Frontali; Randi Jones; Tetsuo Ashizawa; Samuel Frank; Marie-Helene Saint-Hilaire; Steven M Hersch; Herminia D Rosas; Diane Lucente; Madaline B Harrison; Andrea Zanko; Ruth K Abramson; Karen Marder; Jorge Sequeiros; G Bernhard Landwehrmeyer; Ira Shoulson; Richard H Myers; Marcy E MacDonald; James F Gusella
Journal:  Biochem Biophys Res Commun       Date:  2012-07-03       Impact factor: 3.575

5.  Modeling Huntington's disease in cells, flies, and mice.

Authors:  S Sipione; E Cattaneo
Journal:  Mol Neurobiol       Date:  2001-02       Impact factor: 5.590

6.  Functional GluR6 kainate receptors in the striatum: indirect downregulation of synaptic transmission.

Authors:  K Chergui; A Bouron; E Normand; C Mulle
Journal:  J Neurosci       Date:  2000-03-15       Impact factor: 6.167

7.  Replication of twelve association studies for Huntington's disease residual age of onset in large Venezuelan kindreds.

Authors:  J M Andresen; J Gayán; S S Cherny; D Brocklebank; G Alkorta-Aranburu; E A Addis; L R Cardon; D E Housman; N S Wexler
Journal:  J Med Genet       Date:  2006-10-03       Impact factor: 6.318

8.  DNA: where to now?

Authors:  John Beilby
Journal:  Clin Biochem Rev       Date:  2007-05

9.  NR2A and NR2B receptor gene variations modify age at onset in Huntington disease.

Authors:  Larissa Arning; Peter H Kraus; Sandra Valentin; Carsten Saft; Jürgen Andrich; Jörg T Epplen
Journal:  Neurogenetics       Date:  2004-11-17       Impact factor: 2.660

10.  Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease.

Authors:  Birgit Zucker; Dagmar E Ludin; Thomas A Gerds; Carl H Lücking; G Bernhard Landwehrmeyer; Thomas J Feuerstein
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-07-30       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.